# Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

> **NCT00699777** · PHASE1 · COMPLETED · sponsor: **Warner Chilcott** · enrollment: 96 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Risedronate
- **DRUG:** Risedronate

## Key facts

- **NCT ID:** NCT00699777
- **Lead sponsor:** Warner Chilcott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-02
- **Final completion:** 2008-04
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2013-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00699777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00699777, "Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00699777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*